Claritev Corp Stock Price, News & Analysis

Claritev (NYSE: CTEV) announced a strategic relationship with Kinetiq Health to integrate Kinetiq’s claims surveillance, diagnostic second‑opinion services, and cost‑intervention expertise into Claritev’s BenInsights analytics platform.

The combined offering provides monthly medical and pharmacy claims surveillance, risk stratification, and access to a Second Opinion Program to identify emerging high‑cost claims early, support diagnostic certainty, and reduce avoidable spend. From 2020–2024 Kinetiq clients’ average claims trend was 2.48% versus an industry average of 8%.

Claritev (NYSE: CTEV) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT. Management's presentation will be accessible by live webcast and an audio archive via the company's investor relations site: investors.claritev.com/events-and-presentations. For one-on-one meetings, interested parties should contact a representative at the host firm.

Claritev (NYSE: CTEV) announced that its management team will participate in three investor conferences in early December 2025: BofA Securities Leveraged Finance Conference on Dec 2, 2025 at The Boca Raton (presentation ~7:30 AM ET), Citi 2025 Global Healthcare Conference on Dec 3, 2025 at Intercontinental Miami, and Piper Sandler 37th Annual Healthcare Conference on Dec 4, 2025 at Lotte New York Palace (fireside chat 8:00 AM ET).

Where available, live webcasts and audio archives will be posted at investors.claritev.com/events-and-presentations. For one-on-one meetings, attendees should contact representatives at the host firms.

Claritev (NYSE: CTEV) announced an underwritten public offering by selling stockholders of 1,500,000 shares of Class A common stock at $51.50 per share, with a 30-day option for up to an additional 225,000 shares. Claritev will not sell shares and will receive no proceeds from the Offering. The Offering is expected to close by November 14, 2025, subject to customary closing conditions. Joint-lead bookrunning managers are Barclays, Guggenheim Securities and Wells Fargo Securities; Citigroup and Piper Sandler are additional bookrunners. A prospectus supplement will be filed with the SEC; investors should review the prospectus for full details.

Claritev (NYSE: CTEV) announced on November 12, 2025 that certain affiliates of Hellman & Friedman are commencing an underwritten public offering of 1,500,000 shares of Class A common stock, with underwriters granted a 30‑day option to purchase up to an additional 225,000 shares.

Claritev will not sell any shares in the Offering and will not receive proceeds. The underwriters propose to offer the shares to the public at a fixed price that may change. The Offering is subject to market and other conditions and a prospectus supplement will be filed with the SEC.

Claritev (NYSE: CTEV) reported Q3 2025 results with revenues of $246.0 million, up 6.7% year-over-year, and an Adjusted EBITDA of $155.1 million (margin 63.1% vs 61.5% in Q3 2024).

The company recorded a net loss of $69.8 million for Q3 2025 versus a net loss of $391.5 million in Q3 2024. Q3 net cash from operations was $19.9 million and Free Cash Flow was $(16.3) million. Cash and cash equivalents were $39.2 million at quarter end.

Claritev processed ~$45.9 billion in claim charges in Q3, identifying ~$6.1 billion of potential medical cost savings. The company updated FY2025 guidance to revenues +2.8%–3.2% vs FY2024, maintained Adjusted EBITDA margin guidance at 62.5%–63.0%, and reduced capex to $165M–$175M.

Claritev (NYSE: CTEV) announced a strategic investment in Klaim, Inc. to launch a co-branded Payment Acceleration Service across the U.S. and MENA regions on October 27, 2025. The platform combines Claritev’s ACE claim-coding analytics and provider network with Klaim’s AI payment-acceleration technology to convert pending insurance claims into near-instant liquidity, shortening the typical 30–120 day reimbursement cycle.

Key aims include faster, more predictable reimbursements, reduced administrative burden, flexible claim-volume usage, and scalable access for clinics to large hospitals. Klaim also announced a planned global restructuring to unify its Middle East and U.S. operations under a global holding company.

Claritev (NYSE: CTEV) will release its third quarter 2025 financial results on Friday, November 7, 2025 and hold a conference call the same morning at 8:00 AM Eastern Time.

Investors can pre-register for the call via the provided NetRoadshow link to receive a unique PIN and calendar invite; pre-registration remains open up to and after the call start time. A live webcast, supplemental slide deck and the earnings press release will be available in the Investor Relations section at investors.claritev.com/events-and-presentations, and a replay will be archived there after the call.

Claritev (NYSE: CTEV) announced an exclusive strategic agreement with iO Health to license, integrate, and resell iO Health’s Optima AI platform across the Middle East and North Africa (MENA).

The partnership will integrate Optima AI into Claritev’s product suite to target claim-denial reduction, workflow optimization, and improved financial and clinical decision-making for hospitals, clinics, and payors. The companies will collaborate on implementation, integration, and ongoing support to deploy the technology regionally.

The agreement is positioned as a key step in Claritev’s global expansion strategy and aims to accelerate revenue recovery and operational efficiency for MENA healthcare organizations.